163 related articles for article (PubMed ID: 15811211)
1. A randomized, investigator- masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis.
Yee RW; Tepedino M; Bernstein P; Jensen H; Schiffman R; Whitcup SM;
Curr Med Res Opin; 2005 Mar; 21(3):425-31. PubMed ID: 15811211
[TBL] [Abstract][Full Text] [Related]
2. Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.
Heller W; Cruz M; Bhagat YR; De Leon JM; Felix C; Villanueva L; Hollander DA; Jensen H
J Ocul Pharmacol Ther; 2014 Dec; 30(10):815-22. PubMed ID: 25244402
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.
Baiza-Durán L; Olvera-Montaño O; Mercado-Sesma AR; Oregon-Miranda AA; Lizárraga-Corona A; Ochoa-Tabares JC; Pérez-Balbuena AL; Montoya-Sánchez IM; Saucedo-Rodríguez LR; Mora-González A; Gómez-Bastar PA; Villanueva-Najera MA; Sandoval-Delgadillo LI; González-Lomelí M; Páez-Garza JH; Orozco-Carroll M; Casillas-Magallanes M
J Ocul Pharmacol Ther; 2018 Apr; 34(3):250-255. PubMed ID: 29624493
[TBL] [Abstract][Full Text] [Related]
4. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
[TBL] [Abstract][Full Text] [Related]
6. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
Abelson MB; Heller W; Shapiro AM; Si E; Hsu P; Bowman LM;
Am J Ophthalmol; 2008 Jun; 145(6):959-65. PubMed ID: 18374301
[TBL] [Abstract][Full Text] [Related]
7. Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.
Sanfilippo CM; Allaire CM; DeCory HH
Drugs R D; 2017 Mar; 17(1):167-175. PubMed ID: 28078599
[TBL] [Abstract][Full Text] [Related]
8. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis].
Robert PY; Bourcier T; Meddeb-Ouertani A; Khairallah M; Zaghloul K; Amraoui A; Bhagat Y; Pop M; Cochereau I
J Fr Ophtalmol; 2010 Apr; 33(4):241-8. PubMed ID: 20223555
[TBL] [Abstract][Full Text] [Related]
11. A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis.
Kernt K; Martinez MA; Bertin D; Stroman D; Cupp G; Martínez C; Tirado M; Guasch J;
Eur J Ophthalmol; 2005; 15(5):541-9. PubMed ID: 16167284
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
Torkildsen GL; Cockrum P; Meier E; Hammonds WM; Silverstein B; Silverstein S
Curr Med Res Opin; 2011 Jan; 27(1):171-8. PubMed ID: 21138337
[TBL] [Abstract][Full Text] [Related]
13. Oral clindamycin 300 mg BID compared with oral amoxicillin/clavulanic acid 1 g BID in the outpatient treatment of acute recurrent pharyngotonsillitis caused by group a beta-hemolytic streptococci: an international, multicenter, randomized, investigator-blinded, prospective trial in patients between the ages of 12 and 60 years.
Mahakit P; Vicente JG; Butt DI; Angeli G; Bansal S; Zambrano D
Clin Ther; 2006 Jan; 28(1):99-109. PubMed ID: 16490583
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Comstock TL; Paterno MR; Usner DW; Pichichero ME
Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
[TBL] [Abstract][Full Text] [Related]
15. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
16. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
Chang MH; Fung HB
Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
[TBL] [Abstract][Full Text] [Related]
17. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
18. [Comparative research of the efficacy of the gatifloxacin and levofloxacin for bacterial conjunctivitis in human eyes].
Gong L; Sun XH; Qiu XD; Zhang YQ; Qu J; Yuan ZL; Xiong QC
Zhonghua Yan Ke Za Zhi; 2010 Jun; 46(6):525-31. PubMed ID: 21055198
[TBL] [Abstract][Full Text] [Related]
19. Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study.
Leibovitz E; Piglansky L; Raiz S; Greenberg D; Hamed KA; Ledeine JM; Press J; Leiberman A; Echols RM; Pierce PF; Jacobs MR; Dagan R
Pediatr Infect Dis J; 2003 Nov; 22(11):943-9. PubMed ID: 14614364
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients.
Bremond-Gignac D; Mariani-Kurkdjian P; Beresniak A; El Fekih L; Bhagat Y; Pouliquen P; Delval L; Goldschmidt P; Bingen E; Cochereau I
Pediatr Infect Dis J; 2010 Mar; 29(3):222-6. PubMed ID: 19935122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
